ACUR – Q4 2015 Conference Call Thoughts

 

 As a follow up to my original note on ACUR, I just wanted to add some thoughts from the ACUR Q4 2015  conference call, located here  “Dosing in the first cohort of AP-LTX-400 commenced in late February 2016, and the entire cohort is enrolled.”  Enrollment is not an issue – that is positive. “We expect study LTX-400 to complete enrollment, More »

Low-float Acura, Back from the dead, finds itself in the FDA sweet spot

 

 On February 2nd, 2016, President Obama released a statement that he would ask Congress for $1.1 Billion to fight the opioid epidemic, which includes both heroin and abuse of prescription opiates. White House Press Release asking for funding for opiate abuse Coincidentally, this was released the morning after Acura Pharmaceuticals announced they were allowed to resume clinical testing of its abuse-deterrent More »